Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · IEX Real-Time Price · USD
10.56
-0.27 (-2.49%)
At close: Jul 2, 2024, 4:00 PM
10.48
-0.08 (-0.76%)
After-hours: Jul 2, 2024, 7:55 PM EDT
Roivant Sciences Employees
Roivant Sciences had 908 employees as of March 31, 2024. The number of employees increased by 4 or 0.44% compared to the previous year.
Employees
908
Change (1Y)
4
Growth (1Y)
0.44%
Revenue / Employee
$137,439
Profits / Employee
$4,789,566
Market Cap
7.80B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Henry Schein | 25,000 |
| Chemed | 15,087 |
| Bio-Rad Laboratories | 8,030 |
| Bio-Rad Laboratories | 8,030 |
| Exact Sciences | 6,600 |
| HealthEquity | 3,150 |
| Legend Biotech | 1,826 |
| Ascendis Pharma | 879 |
ROIV News
- 4 weeks ago - Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 - GlobeNewsWire
- 2 months ago - Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis - Business Wire
- 3 months ago - Roivant's anti-inflammatory drug succeeds in mid-stage study - Reuters
- 3 months ago - Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million - GlobeNewsWire
- 5 months ago - Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update - GlobeNewsWire
- 6 months ago - Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease - GlobeNewsWire
- 7 months ago - Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease - GlobeNewsWire